Drug Trial Radar · NCT06662773
Drug-Drug Interaction (DDI) Study for TQB3616
Last checked: Nov 19, 2026Latest source record: Oct 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
40
Planned (sponsor's estimate)
Start
Nov 2024
Primary completion
Mar 2025
Study completion Jul 2025
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To evaluate the effect of itraconazole/rifampicin on the pharmacokinetics of TQB3616 capsules. To assess the safety of a single dose of oral TQB3616 capsules and in combination with itraconazole/rifampicin.
Conditions
- Healthy
Interventions
TQB3616 capsule + itraconazoleDrug
C2/4/6 inhibitors + CYP3A metabolic enzyme inhibitors
TQB3616 capsule + rifampicinDrug
C2/4/6 inhibitors + Non-specific cytochrome P450 enzyme inducer
Primary outcomes
What the sponsor says the trial is designed to measure.
- Peak concentration (Cmax)Time frame: Before administration, 1,2,4,6,8,12,24,48,72,120,168,216 hours after administration
- Area under drug time curve (AUC0-t)Time frame: Before administration, 1,2,4,6,8,12,24,48,72,120,168,216 hours after administration
- Area under drug time curve (AUC0-∞)Time frame: Before administration, 1,2,4,6,8,12,24,48,72,120,168,216 hours after administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Tongren Hospital Affiliated to Capital Medical University
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.